about
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateEffects of survivin on FVADT chemotherapy for refractory multiple myeloma.The hypoxia signalling pathway in haematological malignancies.Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.(Immuno)proteasomes as therapeutic target in acute leukemia.Successful eradication of leptomeningeal plasma cell disease.
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Bortezomib for the treatment of multiple myeloma
@ast
Bortezomib for the treatment of multiple myeloma
@en
Bortezomib for the treatment of multiple myeloma
@en-gb
Bortezomib for the treatment of multiple myeloma
@nl
type
label
Bortezomib for the treatment of multiple myeloma
@ast
Bortezomib for the treatment of multiple myeloma
@en
Bortezomib for the treatment of multiple myeloma
@en-gb
Bortezomib for the treatment of multiple myeloma
@nl
prefLabel
Bortezomib for the treatment of multiple myeloma
@ast
Bortezomib for the treatment of multiple myeloma
@en
Bortezomib for the treatment of multiple myeloma
@en-gb
Bortezomib for the treatment of multiple myeloma
@nl
P2093
P2860
P3181
P1476
Bortezomib for the treatment of multiple myeloma
@en
P2093
Andrea Will
Imelda Coyne
Kathleen Scott
Patrick J Hayden
P2860
P3181
P356
10.1002/14651858.CD010816.PUB2
P577
2016-04-20T00:00:00Z